New Amsterdam Partners’s Regeneron Pharmaceuticals REGN Stock Holding History

New Amsterdam Partners’s Portfolio REGN Stock Details REGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q1	$368K	Sell	896 -32	-3%	-$13.2K	0.14%	87
2018 Q4	$347K	Sell	928 -6	-0.6%	-$2.2K	0.11%	93
2018 Q3	$377K	Sell	934 -288	-24%	-$110K	0.1%	96
2018 Q2	$422K	Sell	1,222 -587	-32%	-$184K	0.1%	93
2018 Q1	$623K	Buy	+1,809	New	+$629K	0.14%	93
2017 Q4	–	Sell	-1,143	Closed	-$511K	–	126
2017 Q3	$511K	Hold	1,143	–	–	0.11%	100
2017 Q2	$561K	Sell	1,143 -6	-0.5%	-$2.63K	0.12%	95
2017 Q1	$445K	Buy	+1,149	New	+$426K	0.11%	108

Other funds holding REGN

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Loomis, Sayles & Company Boston, Massachusetts $79.8B AUM 16.05% 1-Year Est. Return

Harris Associates Chicago, Illinois $75.4B AUM 14.46% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Sands Capital Management Arlington, Virginia $26.9B AUM 34.44% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

New Amsterdam Partners's REGN Position: Q1 2019 in Review

New Amsterdam Partners reduced its Regeneron Pharmaceuticals (REGN) stake by 3.4% in Q1 2019, selling an estimated $13.2K and leaving 896 shares worth $368K. The position accounts for 0.14% of the portfolio, ranked #87.

New Amsterdam Partners first reported a position in REGN in Q1 2017 and has held it in 8 quarters since. The position peaked at $623K in Q1 2018. 719 funds tracked by Wall St. Rank hold REGN as of Q1 2019.

New Amsterdam Partners held 896 shares of Regeneron Pharmaceuticals worth $368K as of Q1 2019.
New Amsterdam Partners sold 32 Regeneron Pharmaceuticals shares in Q1 2019, an estimated $13.2K.
Regeneron Pharmaceuticals made up 0.14% of New Amsterdam Partners's portfolio in Q1 2019, its #87 holding.
New Amsterdam Partners first reported a position in Regeneron Pharmaceuticals in Q1 2017 and has held it in 8 quarters since.
New Amsterdam Partners's Regeneron Pharmaceuticals position peaked at $623K in Q1 2018.
719 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q1 2019.

Based on New Amsterdam Partners's 13F filing for Q1 2019, filed 2 May 2019.